A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route
An Open-label, Cross-over, Dose-ranging Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of the Subcutaneous Administration of a Human Plasma-derived C1-esterase Inhibitor in Subjects With Hereditary Angioedema
Sponsor: CSL Behring
Listed as NCT01576523, this PHASE1/PHASE2 trial focuses on Hereditary Angioedema Types I and II and remains completed. Sponsored by CSL Behring, it has been updated 11 times since 2012, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Dec 2022 — Jan 2023 [monthly]
Completed PHASE1_PHASE2
-
Mar 2021 — Dec 2022 [monthly]
Completed PHASE1_PHASE2
▶ Show 6 earlier versions
-
Jan 2021 — Mar 2021 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
-
Jul 2017 — Sep 2017 [monthly]
Completed PHASE1_PHASE2
-
Feb 2017 — Jul 2017 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE1_PHASE2
First recorded
Apr 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CSL Behring
- Parexel
For direct contact, visit the study record on ClinicalTrials.gov .